Elena Fontana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena Fontana has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Ai Ing Lim
Department of Molecular Biology, Princeton University, Princeton, NJ, USA
1 shared publication Alessandra Bandera
Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publication- Alexandra F. Freeman
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
1 shared publication - Amanda Facoetti
Humanitas University, Milan, Italy
1 shared publication - Ana Brett
Hospital Pediátrico, Unidade Local de Saúde de Coimbra 14 , Coimbra
1 shared publication Andrea Farini
Neurology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Dipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection
Effective host defense requires coordinated regulation of immune activation, metabolism, and redox balance, yet how these processes are integrated remains unclear. Here, we identify dipeptidyl peptidase 3 (Dpp3) as a regulator of immune activation thresholds during bacterial infection. Dpp3−/− mice display enhanced resistance to Klebsiella pneumoniae, with early divergence in bacterial burden, improved survival, preserved tissue architecture, and reduced systemic inflammation. Adoptive transfer experiments demonstrate that Dpp3-deficient immune cells are sufficient to confer protection, indicating a cell-intrinsic effect. Mechanistically, Dpp3 deficiency impairs inducible Nrf2 stabilization, resulting in amplified ROS accumulation and enhanced NF-κB–associated responses. Integrated metabolomic, bioenergetic, and proteomic analyses reveal coordinated mitochondrial remodeling and activation of inflammatory signaling networks, consistent with a metabolically primed immune state. Collectively, these findings establish Dpp3 as a systems-level regulator integrating redox control and immunometabolism to calibrate antimicrobial responses during infection.
- 6 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection
Effective host defense requires coordinated regulation of immune activation, metabolism, and redox balance, yet how these processes are integrated remains unclear. Here, we identify dipeptidyl peptidase 3 (Dpp3) as a regulator of immune activation thresholds during bacterial infection. Dpp3−/− mice display enhanced resistance to Klebsiella pneumoniae, with early divergence in bacterial burden, improved survival, preserved tissue architecture, and reduced systemic inflammation. Adoptive transfer experiments demonstrate that Dpp3-deficient immune cells are sufficient to confer protection, indicating a cell-intrinsic effect. Mechanistically, Dpp3 deficiency impairs inducible Nrf2 stabilization, resulting in amplified ROS accumulation and enhanced NF-κB–associated responses. Integrated metabolomic, bioenergetic, and proteomic analyses reveal coordinated mitochondrial remodeling and activation of inflammatory signaling networks, consistent with a metabolically primed immune state. Collectively, these findings establish Dpp3 as a systems-level regulator integrating redox control and immunometabolism to calibrate antimicrobial responses during infection.
- 2 May 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (8)
Immunopathological and microbial signatures of inflammatory bowel disease in partial RAG deficiency
Partial RAG deficiency (pRD) can manifest with systemic and tissue-specific immune dysregulation, with inflammatory bowel disease (IBD) in 15% of the patients. We aimed at identifying the immunopathological and microbial signatures associated with IBD in patients with pRD and in a mouse model of pRD (Rag1w/w) with spontaneous development of colitis. pRD patients with IBD and Rag1w/w mice showed a systemic and colonic Th1/Th17 inflammatory signature. Restriction of fecal microbial diversity, abundance of pathogenic bacteria, and depletion of microbial species producing short-chain fatty acid were observed, which were associated with impaired induction of lamina propria peripheral Treg cells in Rag1w/w mice. The use of vedolizumab in Rag1w/w mice and of ustekinumab in a pRD patient were ineffective. Antibiotics ameliorated gut inflammation in Rag1w/w mice, but only bone marrow transplantation (BMT) rescued the immunopathological and microbial signatures. Our findings shed new light in the pathophysiology of gut inflammation in pRD and establish a curative role for BMT to resolve the disease phenotype.
- 2 May 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (8)
Immunopathological and microbial signatures of inflammatory bowel disease in partial RAG deficiency
Partial RAG deficiency (pRD) can manifest with systemic and tissue-specific immune dysregulation, with inflammatory bowel disease (IBD) in 15% of the patients. We aimed at identifying the immunopathological and microbial signatures associated with IBD in patients with pRD and in a mouse model of pRD (Rag1w/w) with spontaneous development of colitis. pRD patients with IBD and Rag1w/w mice showed a systemic and colonic Th1/Th17 inflammatory signature. Restriction of fecal microbial diversity, abundance of pathogenic bacteria, and depletion of microbial species producing short-chain fatty acid were observed, which were associated with impaired induction of lamina propria peripheral Treg cells in Rag1w/w mice. The use of vedolizumab in Rag1w/w mice and of ustekinumab in a pRD patient were ineffective. Antibiotics ameliorated gut inflammation in Rag1w/w mice, but only bone marrow transplantation (BMT) rescued the immunopathological and microbial signatures. Our findings shed new light in the pathophysiology of gut inflammation in pRD and establish a curative role for BMT to resolve the disease phenotype.